General Information of Drug (ID: DMWYIJ3)

Drug Name
L-708,906 Drug Info
Synonyms
L-708906; CHEMBL19977; SCHEMBL4935528; L-708,906; AC1L9T47; CTK7I3759; BDBM107681; 4-(3,5-dibenzyloxyphenyl)-2,4-dioxo-butanoic acid; 4-[3,5-bis(benzyloxy)phenyl]-2,4-dioxobutanoic acid; 4-(3,5-Bis-benzyloxy-phenyl)-2,4-dioxo-butyric acid; 4-[3,5-bis(phenylmethoxy)phenyl]-2,4-dioxobutanoic acid; (2Z)-4-[3,5-bis(benzyloxy)phenyl]-2-hydroxy-4- oxobut-2-enoic acid (Compound 2)
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
475514
TTD Drug ID
DMWYIJ3

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dolutegravir DMCZGRE Human immunodeficiency virus infection 1C62 Approved [2]
Raltegravir DMYURI6 Human immunodeficiency virus infection 1C62 Approved [3]
Elvitegravir DMG9B1U Human immunodeficiency virus infection 1C62 Approved [2]
Bictegravir, emtricitabine and tenofovir alafenamide DMG0H8K Human immunodeficiency virus infection 1C62 Approved [4]
GSK1265744 DMT8J0I Human immunodeficiency virus infection 1C62 Phase 3 [5]
S-1360 DM9KTSG Human immunodeficiency virus infection 1C62 Phase 2 [6]
S-364735 DMU7ZMH Human immunodeficiency virus infection 1C62 Phase 2 [7]
C-2507 DMOFT1V Human immunodeficiency virus infection 1C62 Phase 1 [8]
Acriflavine DMKVE8X Human immunodeficiency virus infection 1C62 Phase 1 [9]
S-265744 LAP DMDQRWT Human immunodeficiency virus infection 1C62 Phase 1 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Human immunodeficiency virus Integrase (HIV IN) TT5FH9Y POL_HV1B1 Inhibitor [1]

References

1 Specific inhibition of human immunodeficiency virus type 1 (HIV-1) integration in cell culture: putative inhibitors of HIV-1 integrase. Antimicrob Agents Chemother. 2001 Sep;45(9):2510-6.
2 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
3 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
4 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
5 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
6 HIV-1 integrase inhibitors: an emerging clinical reality. Drugs R D. 2007;8(3):155-68.
7 The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral. Antimicrob Agents Chemother. 2008 Mar;52(3):901-8.
8 Elvitegravir: a new HIV integrase inhibitor. Antivir Chem Chemother. 2009 Oct 19;20(2):79-85.
9 Why have ten or so nontoxic, retrovirus integrase inhibitors not been made available for AIDS treatment. Biomed Pharmacother. 1999 Dec;53(10):484-6.
10 Long-acting shot prevents infection with HIV analogue. Nature. doi:10.1038/nature.2014.14819. 04 March 2014